Fundamental Data for QGEN

Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.

# Employees: 1553

Address: Spoorstraat 50 5911 KJ,Venlo,,NLD

Phone: 011-31-77-320-8400

Fax: 49-2103-29-21710

Website: www.qiagen.com

Email: IR@qiagen.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Detlev H. Riesner Dr. (Chmn.)

Heinrich Hornef Dr. (Deputy Chmn.)

Joachim Schorr Dr. (Sr. V.P.; Res. & Devlop.)

Peer M. Schatz (C.E.O.; Mang. Dir.)

Roland Sackers (C.F.O.; Deputy Mang. Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/8/2010

Mean EPS (Next Qtr): $0.24

Mean EPS (Year): $0.90

Mean Estimate(Long Term): $23.83

P/E Ratio(Based on EPS estimate): 23.830

Number of Estimates: 8

Shares Performance

Period	QGEN	Compare to S&P
YTD	22.49 %	1.38 %
4 Weeks	-0.42 %	-1.49 %
12 Weeks	4.82 %	-1.17 %

Shares Information

Analyst Coverage: Y

Avg Volume: 1021935

Shares Outstanding: 199M

Market Cap: $4.28B

52 Week High: $23.13

52 Week Low: $13.86

P/E Ratio: 24.440

PEG Ratio: 1.000

Split: On 7/14/2000 QGEN split by factor of 4.000

Earnings Performance

EPS Growth in Last Quarter: 8.70 %

EPS Growth in Last Year: 19.05 %

Sales Growth in Last Quarter: 8.12 %

Sales Growth in Last Quarter: 12.50 %

Financials

Qtr Book Value: $1.92

Cash Flow/Share: $15.68

Change in Payout Ratio: -0.010

Price/Sales: 4.470